Darren Tan

@NUSMedicine || Interested in all things liver-related, especially liver transplantation and malignancies || Views are my own

[Darren Tan @DarrenTanJH]

🤔 How does NAFLD-related HCC defer from HCC of other causes?
In this paper we evaluate differences in 1️⃣patient and 2️⃣tumor characteristics; and importantly 3️⃣surveillance, 4️⃣tx allocation and 5️⃣survival outcomes

[Daniel Huang @DrHuangDQ]

In this global study of NAFLD-related HCC, we determine:

1.Prevalence
2.Clinical characteristics
3.% cirrhosis
4.Surveillance
5.Treatment allocation
6.Outcomes

#LiverCancerSIG #Livertwitter

Free to read @TheLancetOncol

https://t.co/vwAeicpWxq

1/n

[Daniel Huang @DrHuangDQ]

➡️ Obesity contributed to a ‼️35% increase in cancer deaths in the last decade

➡️ HCC is the fastest growing cause of obesity related cancer deaths
➡️ South East Asia is the fastest growing hot spot

#Metabolism
@CSMantzoros @RashidLui

https://t.co/fdI1Sqspb9

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher

A wide range of mechanisms are being studied; ideal #NASH candidates should be safe and hepatoprotective+cardioprotective
https://t.co/QiwTPypNUf
#MASLD #MASH #LiverTwitter

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Natural history of NASH #cirrhosis in #livertransplant waitlist registrants

Read it here👉https://t.co/5SMJH7KXKs

@WenHuiLim4
#LiverTwitter

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New content online: Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology https://t.co/6LaE68S4PM

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New research - Huang et al - Type 2 diabetes, hepatic decompensation & hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis

https://t.co/nEsc8Vs6AJ

#LiverTwitter #Diabetes #NAFLD #MASLD

[NEJM @NEJM]

Late breaking at #EASLCongress: In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks. Full results by @drloomba et al.: https://t.co/mfRRrV2yX2

[CGH @AGA_CGH]

Study examines impact of type 2 diabetes on the accuracy of noninvasive tests of #liver fibrosis with resulting clinical implications. Learn more at https://t.co/SGpSayDANn.

[The Lancet @TheLancet]

BRAVES is the first randomised trial to compare the effects of bariatric-metabolic surgery with lifestyle modification plus best medical care in people with histologically confirmed non-alcoholic steatohepatitis (NASH).

https://t.co/qf7c6hlK1g🧵

[Daniel Huang @DrHuangDQ]

What is the prevalence of hepatic fibrosis in alpha-1-antitrypsin deficiency (ZZ)?

Significant fibrosis ➡️ 22%

Advanced fibrosis ➡️ 8%

New data @_NAFLDResearch @APandT @DrLoomba @KaiEnChan @ChengHanNg
@GingerClarkMD #LiverTwitter
#GITwitter

https://t.co/VvPaIaHIcD

[Daniel Huang @DrHuangDQ]

Hepatitis B remains the leading cause of global HCC deaths

Underdiagnosis and undertreatment are common

Effective vaccination and antivirals are available but are severely underutilized

@NatRevGastroHep @HsuHolden
#LiverTwitter #GITwitter

https://t.co/tOPTMERdrZ

[GENIAL Project @GENIAL_project]

🌍 Global alcohol consumption 🚀 soaring!
🇪🇺 Europe leads in 🍺🍷
🏥 Alcohol-related liver cancer (ALD-HCC) ranks 3️⃣ in cancer deaths
🚨 ALD-HCC patients face advanced tumors
🔍 Risk factors: amount🍷,obesity, diabetes🚬🧬
https://t.co/M2xWmBpL7Y @EuropeLiver @AleksanderKrag

[Daniel Huang @DrHuangDQ]

Survival trends in sorafenib for advanced #HCC

⬆️ Survival over time

▶️ Median OS now ~13.4 mths (previous 9.8 mths)

⚠️ ?Implications for sample size calculation in trials

@ChengHanNg @ArndtVogel @DrLoomba #livertwitter #GITwitter @KargerPublisher

https://t.co/sv1w6lhIRK

[CGH @AGA_CGH]

The April Editor's Essential Reading examines mortality outcomes by fibrosis stage in #NAFLD. Learn more at https://t.co/4grNRB61x8

[Rohit Loomba @DrLoomba]

SEMAGLUTIDE in Cirrhosis: Significant improvement in ALT and AST and MRI-PDFF with SEMA in cirrhosis-- need longer, larger studies and combination Rx in cirrhosis @UCSD_GI @NAFLDresearch @EASLedu @AASLDtweets @phil_newsome7 @mromerogomez @ebtapper @NoureddinMD @pattymaysent

[Daniel Huang @DrHuangDQ]

The etiology of cirrhosis is changing

⬆️NASH

▶️HBV and HCV declining, but not fast enough

‼️ Disease awareness remains poor

⚠️ Time to focus on early detection?

New paper @_NAFLDResearch @DrLoomba @NatRevGastroHep @NUSMedicine @AASLDPresident

https://t.co/sx0FbUBKz7

[Darren Tan @DarrenTanJH]

@Nicholas_Syn @_ILTS_ @DrMarkMuthiah @WenHuiLim4 @ChengHanNg @DrHuangDQ @dreunicetan @alfredkow Congratulations boss 🎉🎉🤩

[Ramon Bataller @rabataller]

How to manage people with NAFLD ?

🔸How can we identify HIGH RISK patients?
🔸What patients should be referred to a hepatologist?

This review summaries the NAFLD management ALGORITHMS proposed by major international societies.

https://t.co/u4UsjyYsmz #livertwitter #medtwitter

[Dominic Yap @dominicyap_]

Efficacy of ICI in ESCC patients with low PDL1 expression: Our pooled analysis shows there may not be OS benefit in TPS<1% pts. Harmonised biomarkers needed for better pt selection
@FilippoPietran4 @sundar__raghav @NickyWongZH @josephjzhao https://t.co/lvsUXceGu8
@JAMAOnc